Sanofi is taking its three-year-old development collaboration with Selecta Biosciences another big step forward, taking an option on a “negative vaccine” program for celiac disease and putting another $300 million on the table in prospective milestones and research support for a successful program.

…read more

Source: Sanofi doubles down on Selecta collaboration, adding $300M in fresh incentives


0 No comments